# Endpoint Validation Study (0524A-015)

> **NCT00533676** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 165 (—)

## Conditions studied

- Flushing

## Interventions

- **DRUG:** MK0524A, /Duration of Treatment : 8 Weeks
- **DRUG:** Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks

## Key facts

- **NCT ID:** NCT00533676
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 165 (—)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533676, "Endpoint Validation Study (0524A-015)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00533676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*